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Introduction {#j_raon-2017-0058_s_001}
============

Surgery is the cornerstone for treating early-stage non-small cell lung cancer (NSCLC), although radical radiotherapy may be used for medically inoperable cases.[@j_raon-2017-0058_ref_001],[@j_raon-2017-0058_ref_002] In recent years, stereotactic ablative radiotherapy (SABR, or so-called stereotactic body radiotherapy) has been used to deliver radiotherapy instead of conventional fractionated radiotherapy (CFRT).[@j_raon-2017-0058_ref_002],[@j_raon-2017-0058_ref_003],[@j_raon-2017-0058_ref_004],[@j_raon-2017-0058_ref_005] Promising results have been reported for medically inoperable and operable cases and even other cancers.[@j_raon-2017-0058_ref_006],[@j_raon-2017-0058_ref_007],[@j_raon-2017-0058_ref_008],[@j_raon-2017-0058_ref_009]

However, a recent randomized phase II study (the SPACE trial) challenged the general belief that SABR is superior to CFRT, as also mentioned in a 2017 systematic review.[@j_raon-2017-0058_ref_005],[@j_raon-2017-0058_ref_010] It showed that disease control and overall survival were similar for SABR and CFRT, although SABR was better considering some side effects and quality of life. However, this study had limited power (67%), and a larger randomized controlled trial (RCT) is required.[@j_raon-2017-0058_ref_010]

Statement of general knowledge {#j_raon-2017-0058_s_001_s_001}
------------------------------

PubMed for published reports using the keywords (\[*stereotactic radiotherapy*\] OR \[*stereotactic body radiotherapy*\] OR \[*stereotactic ablative radiotherapy*\] OR \[*SBRT*\] OR \[*SABR*\]) AND (\[*non-small cell lung cancer*\] OR \[*NSCLC*\]) AND (\[*survival*\] OR \[*OS*\]) was searched on Sep 2nd 2017, for evidence regarding the efficacy of SABR *vs*. CFRT. In addition to the aforementioned SPACE trial, we identified another small (n = 50) randomized study showing better treatment efficacy for SABR compared to CFRT in peripheral NSCLC.[@j_raon-2017-0058_ref_011] However, patients of various stages (stages I--IV) were included in the study, and the results of stage I patients were not reported. We also found a meta-analysis (published in 2010) that reported better overall survival (OS) for SABR compared to CFRT, but all of the included studies were nonrandomized.[@j_raon-2017-0058_ref_012] In addition, none of the included studies directly compared SABR and CFRT.[@j_raon-2017-0058_ref_012] We also found four subsequent single institutional nonrandomized studies from Europe or North America and two subsequent population-based studies from North America.[@j_raon-2017-0058_ref_013],[@j_raon-2017-0058_ref_014],[@j_raon-2017-0058_ref_015],[@j_raon-2017-0058_ref_016],[@j_raon-2017-0058_ref_017],[@j_raon-2017-0058_ref_018] However, to the best of our knowledge, no population-based study from Asia has compared SABR *vs*. CFRT for treating early-stage NSCLC.

Study aim {#j_raon-2017-0058_s_001_s_002}
---------

Given the relatively limited evidence on this topic, we investigated the effectiveness of SABR *vs*. CFRT for non-operated early-stage NSCLC in a population-based sample from Taiwan.

Patients and methods {#j_raon-2017-0058_s_002}
====================

Data source {#j_raon-2017-0058_s_002_s_001}
-----------

The Health and Welfare Data Science Center (HWDC) database is a set of databases providing complete information regarding the Taiwan cancer registry, death registry, and reimbursement data for the whole Taiwanese population provided by the Bureau of National Health Insurance (NHI).[@j_raon-2017-0058_ref_019] The high quality of this cancer registry has been reported.[@j_raon-2017-0058_ref_020] NHI is a single-payer, compulsory social insurance program that provides insurance coverage to the majority of citizens in Taiwan.[@j_raon-2017-0058_ref_021] All of the above data were included in the HWDC with deidentified personal identifiers.

Identification of study cases and study design {#j_raon-2017-0058_s_002_s_003}
----------------------------------------------

A flowchart showing the identification of study cases appears in [Figure 1](#j_raon-2017-0058_fig_001){ref-type="fig"} as suggested by the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline.[@j_raon-2017-0058_ref_022] Briefly, we identified stage I histology-documented NSCLC patients diagnosed from 2007 to 2013 who received either CFRT or SABR without surgery. We used the date of diagnosis as the index date. We determined the explanatory variable of interest (CFRT *vs*. SABR) based on the record in the cancer registry using the dose/fractionation recommended by the National Comprehensive Cancer Network (NCCN) NSCLC guideline (CFRT: 60--70 Gy in 1.8--2 Gy/fraction; SABR: 25--34 Gy/1 fraction, or 45--60 Gy/3 fractions, or 48--50 Gy/4 fractions, or 50--55 Gy/5 fractions, or 60--70 Gy/8--10 fractions).[@j_raon-2017-0058_ref_001] We also collected other covariate and outcome data from the HWDC. We decided on covariates (age, sex, residency, comorbidity, histology, T stage, period, use of positron emission tomography \[PET\], use of systemic therapy, and previous cancer) based on our clinical and HWDC-related research experiences as well as previous reports.[@j_raon-2017-0058_ref_023],[@j_raon-2017-0058_ref_024],[@j_raon-2017-0058_ref_025] The covariates were defined as follows. Patient residency was classified as northern Taiwan or elsewhere. We included this covariable because geographic practice variation had been report in the literature[@j_raon-2017-0058_ref_026] and we felt it might influence treatment choice in our clinical and research experiences.[@j_raon-2017-0058_ref_024] Comorbidity was defined as with or without a modified Carlson comorbidity score ≥1, as used in our previous NHI cancer study.[@j_raon-2017-0058_ref_024] Histology was classified as adenocarcinoma or non-adenocarcinoma. T stage was classified as T1 *vs*. T2. Period was classified as 2007--2009 or 2010--2013 because staging was changed since 2010. Use of PET, systemic therapy, and previous cancer was classified as yes or no. We used the national death registry to determine survival status and used OS as our endpoint, as initially completed in the SPACE trial.[@j_raon-2017-0058_ref_010] This study was approved by the Research ethics committee at our institute (CMUH104-REC-002).

![The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) study flowchart and the number of individuals at each stage of the study.\
^1^ We only included those treated (class 1--2) at a single institution to ensure data consistency.\
^2^ Sixth (2007--2009) or Seventh (2010--2013) American Joint Committee on Cancer.\
^3^ 60--70 Gy in 1.8--2 Gy/fraction, ±10% in dose.\
^4^ Dose/fraction compatible with National Comprehensive Cancer Network non-small cell lung cancer guideline 2017 v8 (i.e., 25--34 Gy/1 fraction, or 45--60 Gy/3 fractions, or 48--50 Gy/4 fractions, or 50--55 Gy/5 fractions, or 60--70 Gy/8--10 fractions), ±10% in dose.\
^5^Adenocarcinoma or non-adenocarcinoma.\
^6^ Without missing information in the Taiwan cancer registry and death registry.](raon-52-181-g001){#j_raon-2017-0058_fig_001}

Statistical analysis {#j_raon-2017-0058_s_002_s_004}
--------------------

We used the Kaplan-Meier method and log-rank test to compare crude OS between patients treated with SABR *vs*. CFRT. We further used inverse probability weighting (IPW) based on the propensity score (PS) as the primary means of analysis to address the nonrandomization of treatment.[@j_raon-2017-0058_ref_027] We modeled the use of SABR *vs*. CFRT as the dependent variable and the above covariates as independent variables and used logistic regression to model the probability of receiving SABR. Then we used the logit of the probability as the PS, as described previously.[@j_raon-2017-0058_ref_027] Tabulation and standardized differences were used to assess the balance of covariates between treatment groups.[@j_raon-2017-0058_ref_027],[@j_raon-2017-0058_ref_028] We used a weighted Cox model to compare OS between treatment groups for the entire follow-up period (censored on December 31, 2015).[@j_raon-2017-0058_ref_027],[@j_raon-2017-0058_ref_029] We used bootstrap analysis to obtain confidence intervals and p-values, as described previously.[@j_raon-2017-0058_ref_030] For OS results with statistical significance, we further calculated the E-factor to evaluate the robustness of our finding regarding potential unmeasured confounder\[s\] as suggested in the recent literature.[@j_raon-2017-0058_ref_031]

Supplementary analyses {#j_raon-2017-0058_s_002_s_005}
----------------------

In the first supplementary analysis (SA-1), we constructed a subgroup based on PS matching and used a robust variance estimator to compare OS and lung cancer-specific survival of patients treated with SABR *vs*. CFRT. We also used cause of death to obtain lung cancer-specific survival (LCSS). In the second supplementary analysis (SA-2), we constructed another subgroup by PS matching limited to cases from 2011 to 2013 to use the additional covariate (performance status, classified as Eastern Cooperative Oncology Group \[ECOG\] 0--2 *vs*. 3--4) in PS modeling to compare the survival of patients treated with SABR *vs*. CFRT. We limited to this period \[2011--2013\] because performance information was available in Taiwan cancer registry since 2011. SAS 9.4 (SAS Institute, Cary, NC) was used for all analyses.

Results {#j_raon-2017-0058_s_003}
=======

Identification of study cases {#j_raon-2017-0058_s_003_s_001}
-----------------------------

As shown in [Figure 1](#j_raon-2017-0058_fig_001){ref-type="fig"}, we found 238 clinical stage I NSCLC patients who received either SABR or CFRT from 2007 to 2013 were included in our primary analysis. The characteristics of these patients are described in [Table 1](#j_raon-2017-0058_tab_001){ref-type="table"}. Although an imbalance in covariate distribution was observed before PS weighting such as higher percentage of patients with comorbidity received SABR \[32%\] than those without comorbidity \[17%\], a good balance of covariates and small standardized differences (≤ 0.25) were observed for all covariates after we adjusted for PS weighting.[@j_raon-2017-0058_ref_028],[@j_raon-2017-0058_ref_032]

###### 

Patient characteristics for the whole study population

                                                                              SABR           CFRT     Standardized difference (rounded)[^\*^](#j_raon-2017-0058_fn_001){ref-type="table-fn"}                   
  ---------------------------------------------------------- ---------------- -------------- -------- ---------------------------------------------------------------------------------------- -------- ------ ------
  Age                                                                         77.81 (7.85)            75.40 (9.96)                                                                                      0.27   0.24
  Sex                                                        Female           20             \(29\)   44                                                                                       \(26\)   0.07   0.07
  Male                                                       49               \(71\)         125      \(74\)                                                                                                   
  Residency                                                  Non-north        32             \(46\)   93                                                                                       \(55\)   0.17   0.19
  North                                                      37               \(54\)         76       \(45\)                                                                                                   
  Comorbidity                                                Without          9              \(13\)   43                                                                                       \(25\)   0.32   0.25
  With[^†^](#j_raon-2017-0058_fn_006){ref-type="table-fn"}   60               \(87\)         126      \(75\)                                                                                                   
  Histology                                                  Adenocarcinoma   40             \(58\)   82                                                                                       \(49\)   0.19   0.24
  Non-adenocarcinoma                                         29               \(42\)         87       \(51\)                                                                                                   
  T stage                                                    T1               38             \(55\)   49                                                                                       \(29\)   0.55   0.08
  T2                                                         31               \(45\)         120      \(71\)                                                                                                   
  Period                                                     2007--2009       15             \(22\)   65                                                                                       \(38\)   0.37   0.22
  2010--2013                                                 54               \(78\)         104      \(62\)                                                                                                   
  Use of PET                                                 Yes              37             \(54\)   55                                                                                       \(33\)   0.44   0.09
  No                                                         32               \(46\)         114      \(67\)                                                                                                   
  Use of systemic therapy                                    Yes              10             \(14\)   73                                                                                       \(43\)   0.67   0.17
  No                                                         59               \(86\)         96       \(57\)                                                                                                   
  Previous cancer                                            Yes              9              \(13\)   16                                                                                       \(9\)    0.11   0.06
  No                                                         60               \(87\)         153      \(91\)                                                                                                   

CFRT = conventional fractionated radiotherapy; IPW = inverse probability weighting; PET = positron emission tomography; SABR = stereotactic ablative radiotherapy; sd = standard deviation;

rounded at the second

modified Carlson comorbidity score ≥ 1

Primary analysis {#j_raon-2017-0058_s_003_s_002}
----------------

After a median follow-up of 28 months (range 2--105), 171 patients were found to have died (40 SABR and 131 CFRT). We found that SABR led to higher crude OS compared to CFRT, as shown in [Figure 2](#j_raon-2017-0058_fig_002){ref-type="fig"}. The 5-year OS rates for SABR and CFRT were 31% and 20%, respectively (log-rank test, p = 0.0008). After IPW, OS was not significantly different between those treated with SABR *vs*. CFRT (SABR *vs*. CFRT: IPW adjusted hazard ratio \[HR\] 0.586, 95% confidence interval 0.264--1.101, p = 0.102).

![Kaplan-Meier survival curve for the whole study population.\
CFRT = conventional fractionated radiotherapy; SABRT = stereotactic ablative radiotherapy](raon-52-181-g002){#j_raon-2017-0058_fig_002}

Supplementary analyses {#j_raon-2017-0058_s_003_s_003}
----------------------

In SA-1, a good balance of covariates was observed with small standardized differences (≤ 0.25) for the PS-matched subgroup (n = 120; see [Table 2](#j_raon-2017-0058_tab_002){ref-type="table"}). Compared to CFRT, the OS (HR 0.672, p = 0.039) and LCSS (HR 0.529, p = 0.007) of patients receiving SABR were superior. The observed HR 0.672 for OS could be explained away by an unmeasured confounder that was associated with both selections of SABR/CFRT and live/death by a risk ratio of 1.96 fold each, but weaker confounding could not do so. The OS curve is shown in [Figure 3.](#j_raon-2017-0058_fig_003){ref-type="fig"} In SA-2, well-balanced covariates were observed with small standardized differences (≤ 0.25) when cases were limited to 2011 to 2013 with an available performance status (n = 52; see [Table 3](#j_raon-2017-0058_tab_003){ref-type="table"}), although there were some imbalances before matching such as those with poor performance status \[ECOG 3\~4\] were more likely to receive SABR \[60%\] than those with acceptable performance status \[33%\]. We found SABR was associated with further improvement in hazard for death (HR 0.381, p = 0.016) compared to CFRT, as seen in [Figure 4](#j_raon-2017-0058_fig_004){ref-type="fig"}. The observed HR 0.381 for OS could be explained away by an unmeasured confounder that was associated with both selections of SABR/CFRT and live/death by a risk ratio of 3.29 fold each, but weaker confounding could not do so.

###### 

Patient characteristics in the first supplementary analysis

                                                                              SABR           CFRT                             
  ---------------------------------------------------------- ---------------- -------------- -------- -------------- -------- ------
  Age                                                                         77.47 (8.26)            77.75 (9.79)            0.03
  Sex                                                        Female           18             \(30\)   24             \(40\)   0.21
  Male                                                       42               \(70\)         36       \(60\)                  
  Residency                                                  Non-north        29             \(48\)   30             \(50\)   0.03
  North                                                      31               \(52\)         30       \(50\)                  
  Comorbidity                                                Without          9              \(15\)   8              \(13\)   0.05
  With[^†^](#j_raon-2017-0058_fn_012){ref-type="table-fn"}   51               \(85\)         52       \(87\)                  
  Histology                                                  Adenocarcinoma   37             \(62\)   41             \(68\)   0.14
  Non-adenocarcinoma                                         23               \(38\)         19       \(32\)                  
  T stage                                                    T1               30             \(50\)   31             \(52\)   0.03
  T2                                                         30               \(50\)         29       \(48\)                  
  Period                                                     2007--2009       15             \(25\)   15             \(25\)   0.00
  2010--2013                                                 45               \(75\)         45       \(75\)                  
  Use of PET                                                 Yes              30             \(50\)   31             \(52\)   0.03
  No                                                         30               \(50\)         29       \(48\)                  
  Use of systemic therapy                                    Yes              10             \(17\)   13             \(22\)   0.13
  No                                                         50               \(83\)         47       \(78\)                  
  Previous cancer                                            Yes              8              \(13\)   7              \(12\)   0.05
  No                                                         52               \(87\)         53       \(88\)                  

CFRT = conventional fractionated radiotherapy; PET = positron emission tomography; SABR = stereotactic ablative radiotherapy; sd = standard deviation;

rounded at the second

modified Carlson comorbidity score ≥ 1

###### 

Patient characteristics in the second supplementary analysis

                                                                              SABR           CFRT     Standardized difference (rounded)[^\*^](#j_raon-2017-0058_fn_013){ref-type="table-fn"}            
  ---------------------------------------------------------- ---------------- -------------- -------- ---------------------------------------------------------------------------------------- -------- ------
  Age                                                                         76.92 (8.84)            77.73 (9.19)                                                                                      0.09
  Sex                                                        Female           8              \(31\)   7                                                                                        \(27\)   0.09
  Male                                                       18               \(69\)         19       \(73\)                                                                                            
  Residency                                                  Non-north        16             \(62\)   18                                                                                       \(69\)   0.16
  North                                                      10               \(38\)         8        \(31\)                                                                                            
  Comorbidity                                                Without          \#                      \#                                                                                                0.13
  With[^†^](#j_raon-2017-0058_fn_018){ref-type="table-fn"}   \#                              \#                                                                                                         
  Histology                                                  Adenocarcinoma   14             \(54\)   15                                                                                       \(58\)   0.08
  Non-adenocarcinoma                                         12               \(46\)         11       \(42\)                                                                                            
  T stage                                                    T1               11             \(42\)   11                                                                                       \(42\)   0.00
  T2                                                         15               \(58\)         15       \(58\)                                                                                            
  Use of PET                                                 Yes              13             \(50\)   12                                                                                       \(46\)   0.08
  No                                                         13               \(50\)         14       \(54\)                                                                                            
  Use of systemic therapy                                    Yes              \#                      \#                                                                                                0.13
  No                                                         \#                              \#                                                                                                         
  Previous cancer                                            Yes              3              \(12\)   3                                                                                        \(12\)   0.00
  No                                                         23               \(88\)         23       \(88\)                                                                                            
  Performance status                                         ECOG (0--2)      \#                      \#                                                                                                0.00
  ECOG (3--4)                                                \#                              \#                                                                                                         

CFRT = conventional fractionated radiotherapy; ECOG = Eastern Cooperative Oncology Group; PET = positron emission tomography; SABR = stereotactic ablative radiotherapy; sd = standard deviation; \# Exact numbers are not reported because the Health and Welfare Data Science Center (HWDC) database center policy is to avoid numbers in single cells ≤ 2

rounded at the second

modified Carlson comorbidity score ≥ 1

![Kaplan-Meier survival curve for the first supplementary analysis.\
CFRT = conventional fractionated radiotherapy; SABRT = stereotactic ablative radiotherapy](raon-52-181-g003){#j_raon-2017-0058_fig_003}

![Kaplan-Meier survival curve for the second supplementary analysis.\
CFRT = conventional fractionated radiotherapy; SABRT = stereotactic ablative radiotherapy](raon-52-181-g004){#j_raon-2017-0058_fig_004}

Discussion {#j_raon-2017-0058_s_004}
==========

In this population-based PS-adjusted analysis, we provide the first empirical evidence from Asia regarding non-operated early-stage NSCLC patients treated with either SABR or CFRT. We found that OS was not significantly different between those treated with SABR *vs*. CFRT in the primary analysis, although statistical significance was observed in the supplementary analyses.

Our results may be interpreted as compatible with the SPACE trial in that OS was not significantly different between those treated with SABR *vs*. CFRT. On the contrary, because the point estimate of HR for death was around 0.6, SABR may lead to better OS, but the statistical significance was limited by the moderate sample size. The statistical significance found in our SA supported this hypothesis, as reported in other studies from Europe and North America, and indirect comparison in a previous meta-analysis showed that SABR led to better survival.[@j_raon-2017-0058_ref_012],[@j_raon-2017-0058_ref_013],[@j_raon-2017-0058_ref_014],[@j_raon-2017-0058_ref_015],[@j_raon-2017-0058_ref_016],[@j_raon-2017-0058_ref_017],[@j_raon-2017-0058_ref_018] Therefore, our results should not be interpreted as conclusive.

Our study provides additional evidence for practitioners considering SABR in addition to conventional CFRT for non-operated early-stage NSCLC.[@j_raon-2017-0058_ref_033] Although the available randomized data did not support the superior efficacy of SABR compared to CFRT, the power of that study was limited and is not compatible with previous retrospective data.[@j_raon-2017-0058_ref_010] Although the results of our primary analysis were not significant, the trend was in favor of SABR (HR 0.59), and similar trends with statistical significance were observed in SA. Furthermore, we observed that patients with comorbidity or poor performance status were more likely to receive SABR in the pre-matched population (i.e., SABR patients were possibly prone to die from competing death), so it is possible that SABR had improved LCSS \[HR 0.529\] but OS benefit was less obvious \[HR 0.72\] as seen in our SA-1. Therefore, our study may be used by practitioners to select treatment for non-operated early-stage NSCLC while awaiting results from ongoing RCTs (such as NCT01968941 or NCT01014130).

There are some limitations to our study. First, the sample size was moderate, particularly in both supplementary analyses, which severely limits statistical power \[around 0.5 \~ 0.8 in the setting of our SA\]. Second, identification of the study population may be inhomogeneous because a higher dose may be more effective, although we used the NCCN criteria to classify SABR *vs*. CFRT.[@j_raon-2017-0058_ref_034] Third, treatment selection was not random or specified. The reason for choosing radiotherapy but not surgery was not available due to data limitation. In addition, the reason for choosing SABR or CFRT remains unclear. Unobservable bias is possible in retrospective studies, and results of the aforementioned ongoing trials are required. For example, the location of the primary tumor (central *vs*. peripheral) or lung function test results were not known and could have been unbalanced, even after we matched for observable covariates.[@j_raon-2017-0058_ref_035] Epidermal growth factor receptor (EGFR) status may also have been unbalanced. Population variation in treatment response is an emerging issue, and highly prevalent EGFR mutations in Asia (including Taiwan) is a well-known example.[@j_raon-2017-0058_ref_036] Adjuvant EGFR-directed treatment may even improve the outcomes of resected NSCLC.[@j_raon-2017-0058_ref_037] However, we found our result was somehow robust \[E-factor 3.29\] to potential unmeasured confounder(s). Fourth, other endpoints such as local control were not available due to data limitation, although no difference in local control was reported in the SPACE trial.[@j_raon-2017-0058_ref_010]

Conclusions {#j_raon-2017-0058_s_005}
===========

In this population-based PS-adjusted analysis, we provide the first empirical evidence from Asia regarding non-operated early-stage NSCLC patients treated with either SABR or CFRT. We found that OS was not significantly different in the primary analysis between those treated with SABR *vs*. CFRT, although statistical significance was observed in supplementary analyses. Thus, the results of ongoing randomized controlled studies are required.
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